GlassScriptPhysician profile
Kylee B Poudrier
NPI 1629823794
$812.62
in general payments reported to CMS, 2019-2025
14 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $589 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $325.25 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $113.01 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.74 | 2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $54.56 | 2024 | Entyvio |
| Neurocrine Biosciences, INC. | $46.16 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $36.64 | 2025 | Rexulti |
| Lilly USA, LLC | $29.37 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $22.89 | 2024 | |
| Madrigal Pharmaceuticals | $22.77 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $22.11 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.81 | 2025 | Rexulti |
| Evoke Pharma, INC. | $18.61 | 2024 | |
| Celgene Corporation | $15.36 | 2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $15.34 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylee Poudrier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.